Preliminary results of a phase I study: A chimeric monoclonal anti IL-6 antibody CNTO 328 in combination with docetaxel in patients with hormone refractory prostate cancer

被引：0
|
作者：
Hudes, G. R.
Nanus, D.
Qi, M.
Prabhakar, U.
Corringham, R.
Jiao, Q.
Eisenberger, M.
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA
[2] Cornell Univ, New York Presbyterian Hosp, New York, NY 10021 USA
[3] Centocor Inc, Malvern, PA 19355 USA
[4] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
15521
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: Preliminary results
    Ibrahim, N. K.
    Wong, L.
    Rosen, L.
    Shan, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [12] Phase I, multicenter trial of CNTO 328, an anti-interleukin(IL)-6 monoclonal antibody (mAb) in subjects with selected hematologic malignancies.
    Kurzrock, R.
    Voorhees, P.
    Fayad, L.
    Orlowski, R.
    Van Rhee, F.
    Furman, R.
    Borghaei, H.
    Zaki, M. H.
    Prabhakar, U.
    Garay, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 103S - 103S
  • [13] CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) - Preliminary results of subjects with Castleman's disease from a phase 1 study in selected hematological malignancies.
    VanRhee, Frits
    Fayad, Luis
    Borghaei, Hossein
    Voorhees, Peter M.
    Orlowski, Robert Z.
    Furman, Richard R.
    Zaki, Mohamed
    Prabhakar, Uma
    Jiao, Trina
    Lihou, Christine
    Garay, Carlos A.
    Kurzrock, Razelle
    BLOOD, 2006, 108 (11) : 771A - 772A
  • [14] Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results
    George, D. J.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Chen, I.
    Maneval, E. Chow
    Logothetis, C. J.
    Zurita, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [15] Correlation of serum CNTO 328-Anti IL-6 monoclonal antibody (MAb) concentrations and biomarker expression in renal cell carcinoma (RCC) patients.
    Prabhaka, U
    Jang, H
    Jiao, Q
    Ford, J
    Miller, BE
    Graham, MA
    Davis, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 178S - 178S
  • [16] A phase I study of ABT-751 in combination with docetaxel in patients with metastatic hormone-refractory prostate cancer.
    Michels, J. E.
    Ellard, S.
    Le, L.
    Murray, N.
    Guns, E.
    Hagey, A.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 254S - 254S
  • [17] Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: A phase I pharmacokinetic study
    Hervonen, P
    Jekunen, A
    Lefebvre, P
    Kellokumpu-Lehtinen, P
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY RESEARCH, 2003, 23 (01) : 1 - 7
  • [18] A phase I study of ABT-751 in combination with docetaxel in patients with metastatic hormone-refractory prostate cancer.
    Michels, J
    Ellard, S
    Le, LL
    Murray, N
    Guns, E
    Hagey, A
    Chi, KN
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9117S - 9117S
  • [19] SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration- resistant prostate cancer (CRPC)
    Pinski, J. K.
    Goldman, B.
    Dorff, T.
    Mack, P.
    Lara, P., Jr.
    van Veldhuizen, P.
    Quinn, D.
    Hussain, M. H.
    Thompson, I. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [20] Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study
    Fleming, Mark T.
    Rathkopf, Dana E.
    Gibbons, Jackie
    Peterson, Amy C.
    Hannah, Alison
    Forer, David
    Scher, Howard I.
    Morris, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345